Dosage Forms

PharmTech interviewed Sartorius about SUS innovations and trends.

Analytical approaches must keep pace to ensure the identity, safety, and efficacy of evolving mRNA candidates.

Eli Lilly and Company is investing $1 billion to establish a new manufacturing site in Concord, NC, to manufacture parenteral products and devices.

Arranta Bio will use Cytiva’s FlexFactory single-use manufacturing platform to produce mRNA vaccines.

CDMOs offer expertise and capacity for spray drying.

Samsung Biologics has signed an agreement with Biogen to acquire Biogen’s 50% stake in Samsung Bioepis, a joint venture formed by the two companies, for up to $2.3 billion.

Catalent has expanded its Malvern, Pennsylvania, USA, and Dartford, UK, facilities to provide advanced containment capabilities for the micronization of highly potent drug compounds.

In this episode of the Drug Solutions podcast, Chris Spivey, editorial director, and Meg Rivers, senior editor, interview experts on up-and-coming 2022 trends in the bio/pharma industry.

Protective external packaging ensures COVID-19 vaccines arrive safely.

The agreement expands Pfizer’s access to LNP formulation technology for mRNA vaccines and therapeutics.

Intravacc is partnering with Leiden University Medical Center for the development and evaluation of a new intranasal coronavirus vaccine candidate in a clinical Phase I/II study.

Workforce training is crucial for biopharmaceutical manufacturing.

Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.

Fujifilm’s center adds local support in Suzhou, China for cell culture media optimization.

Increased patient-centricity and alternative dosage forms require careful consideration when selecting the best taste-masking approach.

CordenPharma will build a clinical trial development facility for manufacture of oral solid dosage drug products at its Plankstadt facility near Heidelberg, Germany.

Samsung Biologics, GreenLight Biosciences, and Environmental Impact Acquisition Corp. have partnered to advance GreenLight’s mRNA COVID-19 vaccine candidate.

The companies are testing their existing vaccines against the new variant of concern and are pursuing variant-specific versions.

The Comirnaty vaccine received a positive opinion from the EMA’s CHMP for children five to under 12 years of age.

Novavax has announced that EMA has started its review of a conditional marketing authorization application for its COVID-19 vaccine, NVX-CoV2373.

Richard Denk, Senior Consultant Aseptic Processing and Containment, SKAN AG, discusses the evolution of aseptic processing with a particular focus on isolators.

Gernot Warnke, Head of R&D, JRS Pharma, spoke about excipients and how these relate to feeding in batch and continuous manufacturing.

Sharon Nowak, Business Development Manager, Coperion K-Tron USA Food & Pharmaceutical Industries spoke about feeding equipment in solid-dosage drug manufacturing.

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Fernando Muzzio, PhD, Distinguished Professor of Chemical and Biochemical Engineering at Rutgers University, spoke about trends in continuous manufacturing of OSD drugs.

Johannes Khinast, PhD, Institute for Process and Particle Engineering in the Research Center Pharmaceutical Engineering (RCPE) at the Graz University of Technology in Austria, spoke about continuous manufacturing of OSD drugs.

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Dave DiProspero, director of Pharmaceutical Process Technology at CRB, spoke about equipment trends in solid-dosage drug manufacturing.

Alternative drug delivery approaches are promising, but due to their complexity, they need to be sufficiently justified.

Best practices help mitigate generic drug shortages.